Cara Therapeutics, Inc. (NASDAQ:CARA) Given Average Rating of “Hold” by Brokerages

Shares of Cara Therapeutics, Inc. (NASDAQ:CARA) have received an average rating of “Hold” from the five analysts that are presently covering the company, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold recommendation. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $27.84.

Separately, StockNews.com initiated coverage on Cara Therapeutics in a research note on Wednesday, January 8th. They issued a “sell” rating for the company.

Cara Therapeutics Stock Performance

Cara Therapeutics stock opened at $5.20 on Tuesday. The stock has a 50-day moving average of $4.79 and a two-hundred day moving average of $4.04. Cara Therapeutics has a one year low of $2.71 and a one year high of $13.80. The stock has a market cap of $23.76 million, a PE ratio of -0.25 and a beta of 0.50.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. FMR LLC lifted its holdings in Cara Therapeutics by 18.5% in the third quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock valued at $65,000 after acquiring an additional 32,789 shares during the period. Rockefeller Capital Management L.P. acquired a new position in Cara Therapeutics in the fourth quarter valued at approximately $953,000. XTX Topco Ltd purchased a new stake in shares of Cara Therapeutics in the third quarter valued at approximately $29,000. Shay Capital LLC purchased a new stake in shares of Cara Therapeutics in the fourth quarter valued at approximately $524,000. Finally, Curi RMB Capital LLC purchased a new stake in shares of Cara Therapeutics in the fourth quarter valued at approximately $277,000. 44.66% of the stock is owned by institutional investors and hedge funds.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.